

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 2727-130
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5) 09/700434
INTERNATIONAL APPLICATION NO. PCT/EP99/03554	INTERNATIONAL FILING DATE 25 May 1999 (25.04.99)	PRIORITY DATE CLAIMED 22 May 1998 (22.05.98)	
TITLE OF INVENTION TIME-CONTROLLED-RELEASE ACTIVE-INGREDIENT-CONTAINING TRANSDERMAL SYSTEMS			
APPLICANT(S) FOR DO/EO/US Wilfried Fischer			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 			
Items 13 to 20 below concern document(s) or information included:			
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> Certificate of Mailing by Express Mail 20. <input checked="" type="checkbox"/> Other items or information: 			
WIPO publication cover page Declaration (unsigned) 			

532 Rec'd PCT/PTO 15 NOV 2000

U.S. APPLICATION NO. (SEE 37 CFR 1.53) 09/7700434		INTERNATIONAL APPLICATION NO. PCT/EP99/03554		ATTORNEY'S DOCKET NUMBER 2727-130	
--	--	--	--	---	--

21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :			CALCULATIONS PTO USE ONLY		
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$970.00				
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$840.00				
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$690.00				
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$670.00				
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)	\$96.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30		\$0.00			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).				<input checked="" type="checkbox"/>	\$430.00
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30				+	\$0.00
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be:	\$
				refunded	\$
				charged	\$

☐ A check in the amount of _____ to cover the above fees is enclosed.

☒ Please charge my Deposit Account **501145** in the amount of **\$430.00** to cover the above fees.
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **501145** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald R. Santucci
 Pitney, Hardin, Kipp & Szuch, LLP
 711 Third Avenue, 20th Floor
 New York, New York 10017

 (212)687-6000

SIGNATURE
Ronald R. Santucci
 NAME
28,988
 REGISTRATION NUMBER
November 15, 2000
 DATE

2727-130

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (US/DO/EO)

Applicant: Wilfried Fischer
International Appln. No.: PCT/EP99/03554
International Filing Date: 25 May 1999
Priority Date Claimed: 22 May 1998
For: TIME-CONTROLLED-RELEASE ACTIVE-INGREDIENT-CONTAINING
TRANSDERMAL SYSTEMS

PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231
Attn: US/DO/EO

S I R:

Preliminary to examination of the above-identified
application kindly amend the application as follows:

In the Claims:

In claim 3, line 1, kindly delete "one of the preceding
claims" and substitute therefor --claim 1--;;

In claim 4, line 1, kindly delete "any one of the preceding
claims" and substitute therefor --claim 1--;

In claim 5, line 1, kindly delete "any one of the preceding
claims" and substitute therefor --claim 1--;

In claim 6, line 1, kindly delete "any one of the preceding
claims" and substitute therefor --claim 1--;

In claim 7, line 1, kindly delete "any one of claims 2 to
6" and substitute therefor --claim 2--;

650029A01111500

Express Mail No. EK839442726US

In claim 8, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 9, line 1, kindly delete "any one of claims 2 to 8" and substitute therefor --claim 2--;

In claim 10, lines 1-2, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 11, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 12, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 13, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 14, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;


In claim 15, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--;

In claim 16, line 1, kindly delete "any one of the preceding claims" and substitute therefor --claim 1--.

REMARKS

Initially, Applicant wishes to state that this application is entitled to small entity status. The claims of the above referenced application (as they have been amended in the international phase) have been amended to remove all multiple dependencies. No new matter has been added. Accordingly, an early examination of the application is respectfully requested.

Respectfully submitted,


Ronald R. Santucci
Registration No. 28,988

Pitney, Hardin, Kipp & Szuch, LLP
711 Third Avenue, 20th Floor
New York, New York 10017
212-687-6000

Time-controlled-release active-ingredient-containing transdermal systems

The present invention relates to active-ingredient-containing transdermal systems having time-controlled release characteristics. Once applied to the skin, the transdermal systems according to the invention are able to deliver their active ingredient in two or more successive stages at different rates. As a result, unlike with prior art systems, different amounts of active ingredient can be administered to the body at different times during the application period.

Transdermal administration of medicaments by means of transdermal therapeutic systems ("patches") is state of the art medical practice today. Active ingredients for which a uniform level in the blood over time is desirable in order for the medicament to be effective are successfully administered with patches. That category includes active ingredients such as oestradiol, clonidine, fentanyl, scopolamine, flurbiprofen, diclofenac etc.. The pharmacological action of those active ingredients is maintained also when they are administered over a relatively long period, for example a number of days. Those active ingredients can be embedded in a simple manner in so-called matrix patches which are sufficiently known to the person skilled in the art; matrix patches are distinguished from other patch systems by having a purely diffusion-controlled release of active ingredient which can be described by the square root law diffusion equation (Eq. 1) formulated by Higuchi:

$$dQ_t = \frac{1}{2} k_i A t^{\frac{1}{2}}$$

(Eq. 1)

Q	quantity of medicament
k_i	liberation constant
A	surface area
t	time

For homogeneous matrices, k_i is to be substituted in accordance with Eq. 2

$$k_l = \left[Dc_s \left(\frac{2M_0}{V} - c_s \right) \right]^{\frac{1}{2}}$$

(Eq. 2)

D	diffusion coefficient in matrix
c _s	saturation concentration of medicament in matrix
M ₀	amount of active ingredient in matrix, t = 0
V	matrix volume

It will be seen from that equation (1), the basic equation for all matrix-controlled forms of medication, that the delivery of active ingredient is inversely proportional to the square root of the time, that is to say, the amount released steadily decreases with time. For the resulting blood levels, this means in principle a relatively high increase immediately after application and a steady fall over the total application period. A renewed increase in blood levels can be obtained only after exchanging the patch for an unused patch.

A variant of transdermal systems that has a more complex structure is that of membrane patches (for example DE 2 135 533, Alza Corp.). They have been designed with the aim of providing a time-constant delivery of active ingredient. The release of active ingredients is described in Eq. 3 (permeation from reservoir through membranes).

$$\frac{dQ}{dt} = \frac{K_{m/r} K_{a/m} D_a q}{K_{m/r} D_m h_a + K_{a/m} D_a h_m}$$

Eq. 3

dQ/dt	liberation rate
K _{m/r}	distribution coefficient membrane/reservoir
K _{a/m}	distribution coefficient adhesive layer/membrane
D _m	diffusion coefficient in membrane
D _a	diffusion coefficient in adhesive layer
q	quantity of active ingredient

h_m thickness of membrane
 h_a thickness of adhesive layer

According to that equation also, the delivery of active ingredient is steady and, with long times, q becomes smaller, decreasing monotonically. In the case of - undesired - tearing of the membrane, dose dumping can occur, that is to say a release pulse in which, however, no control can be exercised over the release.

In addition to active ingredients that make possible a continuous administration over a relatively long period of time, active ingredients are also known, however, that require variable blood concentrations during the application period. The best-known examples of these, which are also available in transdermal systems, are nitroglycerine, nicotine and testosterone. When supplied continuously, nitroglycerine leads, after a few hours, to a loss in efficacy as a result of a tolerance being developed. In the early years of marketing the products, that factor was not taken into consideration sufficiently, with the result that that type of therapy with nitroglycerine met with only little acceptance among specialists. In keeping with more recent experience of therapy, today the patches are worn only for about 10 to 12 hours and are then removed to create a regeneration phase, so that, in the evening, no protection by nitrates is given. It is precisely in the early hours of the morning, however, that there is an increased incidence of attacks of Angina pectoris. With that method of administration, therefore, no protection is guaranteed unless the patients apply the patches before rising.

The patches for nitroglycerine that are on the market do not take account of that fact that the need for active ingredient varies with the time of day.

The application of nicotine-containing patches is intended to help with giving up smoking. The stimulating effect of nicotine is produced as the nicotine concentration in the blood suddenly rises when a cigarette or the like is smoked. The matrix nicotine patches available on the market, however, are able to produce only a time-constant blood level, which cannot meet the individual nicotine requirement of a smoker.

Physiologically, testosterone is made available to the body systemically in a circadian rhythm. In the early hours at around 8 o'clock, its blood concentration is at its highest,

then falls to a relative minimum towards midday to rise again slightly in the afternoon. During the night, blood levels are at their lowest. WO A 9210231 and DE 195 17 145 describe transdermal systems that, applied in the morning, lead relatively rapidly to a blood level peak which falls again towards midday. The second peak, in the afternoon, cannot be obtained with those systems. The prior art mentioned concerns reservoir systems in which the release of active ingredient begins immediately after application. The active ingredient reservoir substantially consists of alcoholic active ingredient solutions which diffuse into the skin through porous membranes. The membrane saturated with the active ingredient solution is in that case directly in contact with the skin. Such systems are difficult to manufacture and are very expensive.

The problem of the present invention is to provide an inexpensive matrix transdermal system that can be manufactured on standard machines and that meets the requirements of the body's time-dependent need for active ingredient.

In particular, the system is to enable active ingredients to be made available to the human or animal body in a variable manner.

According to the invention, therefore, a transdermal system is provided comprising:

- a) a cover layer (1),
 - b) an active-ingredient-containing polymer layer (3),
 - c) an optionally active-ingredient-containing adhesive layer (4),
- and
- d) a protective layer (5),

characterised in that the active-ingredient-containing polymer layer (3) comprises hydrophilic polymers.

The system according to the invention has the advantage that the hydrophilic polymers of the layer (3) can be etched or dissolved by moisture on the skin, as a result of which a complete breakdown of the layer (3) can occur. The active ingredients are then released and delivered to the skin of the patient in a surge.

By adjusting the loading, thickness, composition, pore size, water-permeability etc. of the layer (4) and optionally also of the layer (3), the time at which the release of active ingre-

dient or active ingredient mixture occurs can be adjusted precisely.

If the layer (4) also contains one or more active ingredients, then active ingredient is slowly delivered to the skin starting from the time of application of the system to the skin. That phase can last until the time when the surge-like active ingredient release of the layer (3) commences.

In a preferred embodiment, the polymers of the layer (3) are soluble in water.

In a preferred embodiment, the layer (3) has perforations (holes) through which the adhesive layer (4) can come into contact with the cover layer (1). Adhesion of the cover layer (1) to the polymer layer (3) is thereby increased. The diameter of the holes can be, for example, from 0.1 to 5 mm, preferably from 0.5 to 2 mm.

The transdermal system according to the invention can have an adhesive layer (2) arranged between the active-ingredient-containing polymer layer (3) and the cover layer (1), which adhesive layer (2) optionally contains active ingredient.

That system is especially advantageous when breakdown of the polymer layer (3) has occurred, since the patch continues to retain its stability.

Especially when the layer (3) is perforated and anchoring bonds pass through the perforation from layer (2) to layer (4), a considerable gain in stability is achieved.

If the layer (2) contains one or more active ingredients, then active ingredient can continue to be delivered slowly to the skin after the surge-like release by the layer (3).

The cover layer (1) comprises according to the invention materials customary *per se*, such as one or more water-vapour-impermeable materials, such as polyterephthalic acid ester or polypropylene, or one or more water-vapour-permeable materials, such as polyurethane, or one or more woven or non-woven fabrics.

In a preferred embodiment, the adhesive layer (4) and, where applicable, the adhesive layer (2) are, independently of each other, pressure-sensitive adhesive layers.

According to the invention, the active ingredient(s) in the polymer layer (3) is(are) preferably not miscible with water.

Suitable hydrophilic polymers are, for example, gelatin or cellulose esters or ethers or derivatives thereof.

The active ingredients used according to the invention can be present in the relevant layers in the form of immobilised active ingredient solution(s) or dispersion(s).

The protective layer (5) can be a re-detachable protective layer customary *per se* and can comprise a siliconised film or a silicone paper.

The transdermal system according to the invention can be so constructed that

- a) the layers (2) and (4) are free of active ingredient, or
 - b) the layer (2) contains active ingredient and the layer (4) is free of active ingredient, or
 - c) the layer (2) is free of active ingredient and the layer (4) contains active ingredient, or
 - d) the layers (2) and (4) contain active ingredient,
- the thickness of the layer (4) being from 10 to 300 μm , preferably from 30 to 100 μm , and the thickness of the layer (2) being from 1 to 300 μm , preferably from 3 to 100 μm .

Suitable active ingredients are, for example, testosterone, nitroglycerine, nicotine or mixtures thereof.

Accordingly, the transdermal system according to the invention can be used, for example, for the treatment of Angina pectoris, for nicotine withdrawal or in the case of testosterone deficiency symptoms.

A process according to the invention for the manufacture of a transdermal system according to the invention is characterised in that an adhesive layer (4) is applied to a protective layer (5), an active-ingredient-containing hydrophilic polymer layer (3) optionally having perforations is applied to the adhesive layer (4), a further adhesive layer (2) is optionally applied to the polymer layer (3) and a cover layer (1) is applied to the top layer.

The transdermal system according to the invention consists, therefore, of a multi-layer laminate, comprising a cover layer (backing, layer (1)) which can be water-vapour-impermeable, such as polyterephthalic acid ester or polypropylene, or water-vapour-permeable, such as polyurethane, or a woven or non-woven fabric. Optionally applied to that cover layer is a pressure-sensitive adhesive layer (anchoring, layer (2)); pressure-sensitive adhesives are sufficiently known to any person skilled in the art, either applied from solution or dispersion or in solvent- or dispersant-free form. That layer can contain active ingredient or be free of active ingredient; preferably, it is free of active ingredient. Applied to that adhesive layer is a layer (layer (3)) comprising or consisting of a polymer layer and an active ingredient solution or dispersion immobilised in the polymer layer. The polymer is preferably a water-soluble polymer, such as gelatin or cellulose esters or ethers. There is incorporated into the water-soluble polymer (polymer layer (3)), for example, a non-water-miscible active ingredient solution or dispersion which may form the sole active ingredient reservoir or part of the total active ingredient reservoir. Applied to the polymer layer is a further layer (layer (4)) of a pressure-sensitive adhesive which is provided for fixing the system to the skin. That layer can contain active ingredient or be free of active ingredient. It comprises or consists of, for example, the pressure-sensitive adhesives known to the person skilled in the art, which again can be applied from solution or dispersion or in a solvent- or dispersant-free form. Anchoring bonds can be passed through holes in the polymer layer (3) to join layer (2) to layer (4). Applied to the last-mentioned layer is a re-detachable protective layer (layer (5)), usually a siliconised film or a silicone paper, which is removed before the system is applied to the skin.

To explain the mode of operation of the system according to the invention, four cases can be differentiated (see Fig. 1):

i. layer (2) and layer (4) are free of active ingredient

Since the polymer active ingredient layer (layer (3)) can consist of or comprise one or more water-soluble polymer(s), the moisture on the skin has to penetrate into that layer and etch it or dissolve it in order to allow the active ingredient immobilised in it, for example in the form of emulsion droplets, to diffuse out. The breakdown of the layer (3), which occurs more or less rapidly, for example depending on the degree of loading of the layer, results in the surge-like release of a large quantity of the active ingredient which can

penetrate rapidly through the layer (4) into the skin.

Another advantage of the system according to the invention in comparison with conventional matrix systems is that, after the system has been stuck to the skin, no active ingredient delivery takes place for a time that is to be pre-set, but then a surge-like delivery of active ingredient takes place. The time can be pre-set, for example, by adjusting the thickness of the layer (4), its composition, pore size, water-permeability etc..

ii. layer (2) contains active ingredient, layer (4) is free of active ingredient

After the depletion of the polymer layer (3) described in i., further active ingredient can subsequently diffuse out of the layer (2) and begin a second, continuous release period. That construction can be used advantageously for active ingredients such as testosterone, with which, after an initially rapid release component, a slower, continuously releasing dose component is required.

iii. layer (2) is free of active ingredient, layer (4) contains active ingredient

With this construction of the system according to the invention, continuous release of active ingredient begins immediately after application from the layer (4). After a lag time determined by the thickness and composition etc. of the layer (4), the rapid release of the active ingredient component of the layer (3) described in i. begins. These systems can be used advantageously in cases where, for example, no symptoms or only mild symptoms appear at times when the body is resting, but those symptoms become markedly more severe at times when activities are begun. It is known, for example, of organic nitrates which are used in the treatment of coronary heart disease that they are most effective in the morning hours at the time when heart attacks are most frequent. In phases of relative rest by the body, on the other hand, the need for nitrate is lower. Such a system could, therefore, be applied in the evening, delivering only relatively little active ingredient during the time of rest, in order in the morning, after the appropriately set lag time, to deliver more active ingredient to the body.

iv. layer (2) and layer (4) contain active ingredient

With this construction of the transdermal system according to the invention, continuous release of the active ingredient begins after application from the layer (4), reaches its maximum value after the lag time, to be continued slowly and continuously again from the layer (2) after depletion of the polymer layer (3).

Manufacturing Process

The pressure-sensitive adhesive layer (layer (4)) is applied - with or without active ingredient dissolved or dispersed therein - to the siliconised protective layer (layer (5)). The layer can be applied from solution in organic solvents, such as *inter alia* ethyl acetate, hexane, from solution or dispersion in aqueous solvents or also in solvent-free form by means of melt-coating or by *in situ* polymerisation. The thickness of that layer can be from 10 to 300 μm , preferably from 30 to 100 μm . The active ingredient(s) contained therein can be truly dissolved or can be in microdisperse form. Combinations of a plurality of active ingredients can be used.

In a separate step, the active-ingredient-containing polymer layer (layer (3)) is manufactured by emulsifying, for example, a solution or dispersion of one or more active ingredients in a non-volatile or sparingly volatile solvent in an aqueous solution or melt of a hydrophilic polymer. The emulsion is spread onto an intermediate film. As the emulsion solidifies, liquid-filled pores, for example, form in the polymer layer. That layer is subsequently dried and produces a film in which the active ingredient solution/dispersion is present in immobilised droplets. The polymer layer can then be provided with holes having diameters of from 0.1 to 5 mm, preferably from 0.5 to 2 mm, by punching. Then, with the protective film removed, the perforated polymer layer can be laminated onto the layer (4).

In a further step, the layer (2) - with or without active ingredient dissolved or dispersed therein - is then applied to the cover layer (layer (1)). The adhesive layer can be applied from solution in organic solvents, such as *inter alia* ethyl acetate, hexane, from dispersion in aqueous solvents or also in solvent-free form by means of melt-coating or by *in situ* polymerisation. The thickness of that layer can be from 1 to 300 μm , preferably from 3 to

100 μm . The active ingredient contained therein can be truly dissolved or can be in microdisperse form. Combinations of a plurality of active ingredients can be manufactured. After curing of that layer, it is laminated onto the polymer layer (3). The adhesive layer can join with the adhesive layer (4) through the optional punched holes in the layer (3). A stable bonding-together of the system is thereby ensured even if the polymer layer (3) were to be dissolved completely during application of the system.

After punching the appropriate shape from the laminate, the transdermal system is complete.

The invention further relates to a transdermal system comprising

- a) an active-ingredient-impenetrable cover layer (11),
 - b) a hydrophilic and slightly water-soluble membrane,
 - c) an adhesive layer (14) fixed adhesively to the membrane and optionally containing active ingredient and
 - d) a detachable protective layer (15),
- the cover layer (11) and the membrane forming with each other a cavity
 - into which the active ingredient in a liquid medium has been introduced,
 - the cover layer (11) and the membrane being inert towards the active-ingredient-containing liquid medium.

The further transdermal system according to the invention can be characterised by a membrane of gelatin, agar, starch or a synthetic hydrophilic and slightly water-soluble polymer material.

The further transdermal system according to the invention can also be characterised in that the cover layer (11) is joined in a ring to the membrane or is joined directly to the adhesive layer (14).

The further transdermal system according to the invention can also be characterised in that the active ingredient is present in the form of a solution in a solvent, especially in a natural or synthetic oil, preferably turpentine oil, silicone oil or neutral oil, or in a volatile organic solvent, preferably heptane, or in a mixture thereof.

A transdermal system according to the invention can be characterised in that the cover layer (1, 11) comprises one or more water-vapour-impermeable material(s), especially polyester, preferably polyterephthalic acid ester, or polypropylene or polyethylene, or one or more water-vapour-impermeable material(s), especially polyurethane, or one or more woven or non-woven fabrics.

A transdermal system according to the invention can also be characterised in that the adhesive layer (4, 14) and/or the adhesive layer (2) are, independently of each other, pressure-sensitive adhesive layers.

A transdermal system according to the invention can also be characterised in that the adhesive layer (4, 14) and/or the adhesive layer (2) contain a net, a non-woven fabric or a woven fabric, the thread or fibre thickness thereof preferably being less than the thickness of the adhesive layer.

A transdermal system according to the invention can also be characterised in that the protective layer (5, 15) is re-detachable and is especially a siliconised plastics film or a silicone paper.

Finally, a transdermal system according to the invention can be characterised in that the active ingredient comprises testosterone, nitroglycerine or mixtures thereof.

Finally, the invention relates to the use of a transdermal system according to the invention for the treatment of Angina pectoris, for nicotine withdrawal or in the case of testosterone deficiency symptoms.

Examples

1. Testosterone-containing reservoir transdermal system

The Example describes a reservoir system in which testosterone is dissolved in a terpene-containing vegetable oil. Figure 1 shows the *in vitro* skin permeation characteristic of that system together with the Comparison Example. The Comparison Example does not contain any element that delays active ingredient permeation and

shows the permeation of testosterone purely through an adhesive membrane. The test preparations were adhesively affixed to the isolated skin of nude mice and the active ingredient diffusion was examined in known Franz cells. It becomes clear that, after a lag time of approximately 15 hours, the release of active ingredient commences almost spontaneously and exhibits a permeation rate like that of the Comparison Preparation. Further tests have shown that the length of the lag time depends on the thickness and nature of the lag time layer.

1.1. Manufacture of the adhesive layer

A commercially customary pressure-sensitive adhesive (Duro-Tak 2070) is applied by means of a suitable coating device (for example a reverse roll coater) to a siliconised carrier film (for example polyterephthalic acid ester) in such a manner that a weight per unit area of the dried adhesive of 30 g/m² results.

1.2. Manufacture of the lag time layer

10 g of gelatin, 0.2 g of polysorbate 80, 4.02 g of glycerine and 25.8 g of water are heated to approximately 80°C. Having cooled to 50°C, the gelatin solution is applied by means of a suitable coating device (for example a reverse roll coater) to a carrier film (for example polyterephthalic acid ester) in such a manner that a weight per unit area of the dried gelatin of 45 g/m² results.

1.3. Manufacture of the active ingredient solution

Testosterone is dissolved to saturation point in a terpene-containing vegetable oil (concentration: 8.6 %).

1.4. Manufacture of the transdermal system

Circular portions having a diameter of 1.5 cm are punched from the lag time layer from 1.2. The portions are pressed onto the non-covered side of the adhesive layer from 1.1. Circular portions having a diameter of 2 cm are cut from a polyterephthalic acid ester film having a thickness of 15 µm (cover film). In a suit-

able assembly machine, those film portions are placed centrally on the pieces of gelatin film and are stuck to the underlying adhesive layer while simultaneously introducing, by means of a filling needle, 0.5 ml of the active ingredient solution into the cavity formed between the gelatin film and the cover film. After withdrawing the filling needle, the filling opening is sealed and the transdermal systems having a diameter of 2 cm are punched out.

2. Testosterone-containing matrix transdermal system

The Example describes a matrix system in which an oily testosterone solution is immobilised in a hydrophilic polymer.

Figure 2 shows the *in vitro* skin permeation of a matrix system together with the Comparison Example under the conditions described in 1. A lag time of approximately 3 hours can clearly be seen.

2.1. Manufacture of the adhesive layer as described in 1.1.

2.2. Manufacture of the cover film with anchoring layer

A commercially customary pressure-sensitive adhesive (Duro-Tak 2070) is applied by means of a suitable coating device (for example a reverse roll coater) to a carrier film (for example polyterephthalic acid ester) in such a manner that a weight per unit area of the dried adhesive of 3 g/m² results.

2.3. Manufacture of the active ingredient solution as described in 1.3.

2.4. Manufacture of the active-ingredient-containing hydrophilic polymer layer

10 g of gelatin, 2.32 g of glycerine, 0.51 g of polysorbate 80 and 26 g of water are processed at approximately 60°C to form a homogenous solution. 8 g of the active ingredient solution from 2.2. are emulsified in the gelatin solution at 75°C. The emulsion is applied by means of a suitable coating device (for example a reverse roll coater) to a carrier film (for example polyterephthalic acid ester) in such a manner

that a weight per unit area of the dried gelatin with incorporated active ingredient solution of 32 g/m² results.

2.5. Manufacture of the transdermal systems

The active-ingredient-containing gelatin layer is laminated onto the non-covered side of the adhesive layer from 2.1. The adhesive layer of the cover film is in turn laminated onto the gelatin layer. The then five-layered laminate, consisting of cover film, anchoring layer, active-ingredient-containing gelatin layer, adhesive layer and siliconised polyester film, is processed in a suitable punching or cutting apparatus to form transdermal systems having a diameter of, for example, 2 cm. After removal of the siliconised polyester film, the system can be stuck onto the skin by the pressure-sensitive adhesive layer.

3. Glycerine trinitrate-containing matrix transdermal system

The Example describes a matrix system in which an oily glycerine trinitrate solution is incorporated into a gelatin layer and combined with a glycerine trinitrate-containing adhesive layer.

3.1. Manufacture of the glycerine trinitrate-containing adhesive layer

Glycerine trinitrate is dissolved in a solution of Duro-Tak 2052 in an amount such that a 10 % concentration in respect of the solids content is obtained. The solution is applied by means of a suitable coating device (for example a reverse roll coater) to a carrier film (for example siliconised polyterephthalic acid ester film) in such a manner that a weight per unit area of the dried adhesive of 50 g/m² results.

3.2. Manufacture of the glycerine trinitrate-containing gelatin layer

10 g of gelatin, 2.32 g of glycerine, 0.51 g of polysorbate 80 and 26 g of water are processed at approximately 60°C to form a homogeneous solution. 8 g of a commercially customary 10 % solution of glycerine trinitrate in neutral oil are emulsified in the gelatin solution at 75°C. The emulsion is applied by means of a suitable

coating device (for example a reverse roll coater) to a carrier film (for example polyterephthalic acid ester) in such a manner that a weight per unit area of the dried gelatin with the incorporated active ingredient solution of 40 g/m² results.

3.3. Manufacture of the cover film with anchoring layer as in 2.2.

3.4. Manufacture of the transdermal systems

Manufacture is carried out as described in 2.5.

4. Comparison Example

The manufacture of the transdermal system is carried out analogously to Example 1, omitting the lag time layer.

Patent Claims

1. A transdermal system comprising:
- a) a cover layer (1, 11),
 - b) a water-soluble material that can be dissolved by moisture on the skin,
 - c) an optionally active-ingredient-containing adhesive layer (4, 14),
- and
- d) a protective layer that is detachable therefrom,
- the transdermal system being characterised by an active-ingredient-containing polymer layer (3) in which the active ingredient is present in the form of a non-water-miscible active ingredient solution or a non-water-miscible active ingredient dispersion in a water-soluble polymer.
2. A transdermal system according to claim 1, **characterised** by an adhesive layer (2) arranged between the active-ingredient-containing polymer layer (3) and the cover layer (1), which adhesive layer (2) optionally contains active ingredient.
3. A transdermal system according to one of the preceding claims, **characterised** in that the active ingredient(s) in the polymer layer (3) is(are) not miscible with water.
4. A transdermal system according to any one of the preceding claims, **characterised** in that the hydrophilic polymer comprises gelatin or cellulose esters or ethers or derivatives thereof.
5. A transdermal system according to any one of the preceding claims, **characterised** in that the polymer layer (3) is perforated, so that at least the adhesive layer (4) can come into contact with layers (1, 2) disposed on the other side of the polymer layer (3).
6. A transdermal system according to any one of the preceding claims, **characterised** in that the active ingredients are present in the relevant layers in the form of (an) immobilised active ingredient solution(s) or dispersion(s).
7. A transdermal system according to any one of claims 2 to 6, **characterised** in that
- a) the layers (2) and (4) are free of active ingredient, or

- b) the layer (2) contains active ingredient and the layer (4) is free of active ingredient, or
- c) the layer (2) is free of active ingredient and the layer (4) contains active ingredient, or
- d) the layers (2) and (4) contain active ingredient.

8. A transdermal system according to any one of the preceding claims, **characterised** in that the thickness of the layer (4) is from 10 to 300 μm , preferably from 30 to 100 μm .

9. A transdermal system according to any one of claims 2 to 8, **characterised** in that the thickness of the layer (2) is from 1 to 300 μm , preferably from 3 to 100 μm .

10. A process for the manufacture of a transdermal system according to any one of the preceding claims, **characterised** in that, in a freely selectable order, an adhesive layer (4) is applied to a protective layer (5), an active-ingredient-containing polymer layer (3) optionally having perforations is applied to the adhesive layer (4), a further adhesive layer (2) is optionally applied to the polymer layer (3), and a cover layer (1) is applied to the top layer.

11. A transdermal system according to any one of the preceding claims, **characterised** in that the cover layer (1, 11) comprises one or more water-vapour-impermeable material(s), especially polyester, preferably polyterephthalic acid ester, or polypropylene or polyethylene, or one or more water-vapour-impermeable material(s), especially polyurethane, or one or more woven or non-woven fabrics.

12. A transdermal system according to any one of the preceding claims, **characterised** in that the adhesive layer (4, 14) and/or the adhesive layer (2) are, independently of each other, pressure-sensitive adhesive layers.

13. A transdermal system according to any one of the preceding claims, **characterised** in that the adhesive layer (4, 14) and/or the adhesive layer (2) contain a net, a non-woven fabric or a woven fabric, the thread or fibre thickness thereof preferably being less than the thickness of the adhesive layer.

14. A transdermal system according to any one of the preceding claims, **characterised** in that the protective layer (5, 15) is re-detachable and is especially a siliconised plastics

15. A transdermal system according to any one of the preceding claims, **characterised** in that the active ingredient comprises testosterone, nitroglycerine or mixtures thereof.

16. The use of a transdermal system according to any one of the preceding claims for the treatment of Angina pectoris, for nicotine withdrawal or in the case of testosterone deficiency symptoms.

Abstract

The present invention relates to a transdermal system comprising:

- a) a cover layer (1),
- b) an active-ingredient-containing polymer layer (3),
- c) an optionally active-ingredient-containing adhesive layer (4),
- and
- d) a protective layer (5),

characterised in that the active-ingredient-containing polymer layer (3) comprises hydrophilic and/or water-soluble polymers.






Fig. 1

In vitro skin permeation testosterone Example 1 v. Comparison Example



In vitro skin permeation testosterone Example 2 v. Comparison Example



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number 2727-130

First Named Inventor Wilfried Fischer

COMPLETE IF KNOWN

Application Number 09 / 700,434

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Time-Controlled-Release Active-Ingredient-Containing Transdermal Systems"

the specification of which

(Title of the invention)

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY) 05/25/1999 as United States Application Number or PCT International

Application Number PCT/EP99/03554 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
DE19823027.3	Germany	05/22/1998	<input type="checkbox"/>	YES	NO
DE19844079.0	Germany	09/25/1998	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

(Page 1 of 2)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

(July 1998)

Express Mail #EF321729671US

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer Number Bar Code Label here

Name	Registration Number	Name	Registration Number
Joseph C. Sullivan	18,720	John F. Gulbin	33,180
Gerald Levy	24,419		
Ronald R. Santucci	28,988		
Ronald E. Brown	32,200		


☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number OR ☒ Correspondence address below

Name	Ronald R. Santucci				
Address	Pitney, Hardin, Kipp & Szuch LLP				
Address	711 Third Avenue, 20th Floor				
City	New York	State	NY	ZIP	10017
Country	U.S.A.	Telephone	212-687-6000	Fax	212-682-3485

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname	
Wilfried		Fischer	
Inventor's Signature			Date
Residence: City	Munich	State	Germany
Post Office Address	Frankfurter Ring 193a		
Post Office Address			
City	Munich	State	Germany
ZIP	D-80807	Country	Germany

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto